Background: Ovarian cancer and ovarian related diseases affect reproductive health.
Therapeutic molecules are needed to improve treatment outcomes and overcome drug resistance.
The benzimidazole-based sulphonamide LLW-3-6 has both anti-apoptotic and anti-proliferative
effects when used to treat prostate, breast, and brain cancer cells.
Objective: The study described herein evaluates the anti-proliferative and anti-migratory effects of
LLW-3-6 SKOV-3 ovarian cystadenocarcinoma cell line.
Methods: Studies were conducted using SKOV-3 cells treated with LLW-3-6. The cell line was
propagated and proliferative activity was evaluated by hemocytometric and MTT colorimetric
assays. Cellular apoptosis was assessed using Caspase-3 spectrophotometric analysis. Lastly, a
scratch wound assay was conducted in a dose and time-dependent manner to assess the effect of
LLW-3-6 on migration.
Conclusion: Proliferative studies suggest, SKOV-3 cells exposed to LLW-3-6 in culture resulted in
decreased growth and proliferation of cells in a time and dose-dependent manner. The apoptotic
effect of this agent was noted with the confirmed presence of Caspase-3 in a dose and timedependent
manner as well. Preliminary studies also suggest an anti-migratory effect of LLW-3-6,
confirmed by scratch wound analysis. LLW-3-6 is potentially a chemotherapeutic option for
decreasing proliferation and inducing apoptosis in ovarian carcinomas. Additional biological
analysis is ongoing to further assess the utility of the molecule and its mechanism of action.